VYNE THERAPEUTICS INC.

(VYNE)
  Report
Real-time Estimate Cboe BZX  -  05/16 11:33:53 am EDT
0.4000 USD   +0.48%
05/12VYNE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Loss $-0.14
MT
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Revenue $178,000
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)

01/19/2022 | 08:03am EDT

Item 8.01 Other Events.

On January 19, 2022, VYNE Therapeutics Inc. (the "Company") issued a press release entitled "VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

In addition, the Company updated its investor presentation to include a slide (slide 13) detailing the Phase 1b data. The updated investor presentation can be found in the "Events & Presentations" section of the Company's website, https://vynetherapeutics.com/investors-media/events_presentations/.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits


The following exhibit is being filed herewith.



Exhibit No.  Description

  99.1         Press Release, dated January 19, 2022.

             Cover Page Interactive Data File (embedded within the Inline XBRL
104          document)

© Edgar Online, source Glimpses

All news about VYNE THERAPEUTICS INC.
05/12VYNE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Loss $-0.14
MT
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Revenue $178,000
MT
05/12VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2..
CI
05/12VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Up..
AQ
05/12NORTH AMERICAN MORNING BRIEFING : Stocks Seen -3-
DJ
05/10VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform
AQ
05/06VYNE Therapeutics to Present at LifeSci Partners' Immunology & Inflammation Symposium o..
AQ
04/08SECTOR UPDATE : Health Care Stocks Edge Upward Premarket Friday
MT
04/07VYNE Therapeutics Reports 'Positive' Efficacy Results From Phase 1b Portion of Atopic D..
MT
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 0,43 M - -
Net income 2022 -37,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,68x
Yield 2022 -
Capitalization 23,0 M 23,0 M -
Capi. / Sales 2022 53,1x
Capi. / Sales 2023 5,48x
Nbr of Employees 28
Free-Float 93,9%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,40 $
Average target price 5,80 $
Spread / Average Target 1 357%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-60.97%23
JOHNSON & JOHNSON3.38%465 363
PFIZER, INC.-15.46%280 096
ABBVIE INC.13.37%271 251
ELI LILLY AND COMPANY5.58%262 514
ROCHE HOLDING AG-15.85%258 421